Brightgene Bio-medical Technology Co., Ltd.

This early-stage trial tested a new drug called BGM0504, given as a weekly injection, in 30 non-diabetic adults who were overweight or obese. The main goals were to check safety, how the body processes the drug, and any changes in weight. Participants received either a low dose, …

This study looked at how quickly the drug BGM0504 enters the blood and how long it stays in the body. Researchers compared 34 people with normal kidney function to those with mild or moderate kidney problems. The goal is to understand if kidney function changes how the drug shoul…

This completed Phase 1 trial tested how a new injectable drug, BGM0504, affects stomach emptying and the absorption of two common medications—metformin and warfarin—in 28 overweight or obese adults. Participants received BGM0504 alongside these drugs to measure changes in drug le…